News from intarcia therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Oct 01, 2014, 22:35 ET

Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results

 Intarcia Therapeutics, Inc. today announced successful top-line results from two of its four phase 3 clinical trials for ITCA 650 (exenatide,...

Sep 19, 2014, 05:46 ET

Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes

Intarcia Therapeutics, Inc. today announced the presentation of positive interim clinical data for its lead candidate ITCA 650 (continuous...

Sep 17, 2014, 08:15 ET

Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies

Intarcia Therapeutics, Inc. today announced the presentation of compelling, quantitative data from a study of the cost and predictability of...

Sep 11, 2014, 17:01 ET

Intarcia Announces Two Presentations At 50th EASD Meeting: Confirms Pivotal Phase 3 Data Announcement For ITCA 650 In Type 2 Diabetes In 4Q

 Intarcia Therapeutics, Inc. today announced its participation in the 50th Annual Meeting of the European Association for the Study of Diabetes...

Aug 05, 2014, 09:03 ET
Sunita Zalani, Ph.D. (PRNewsFoto/Intarcia Therapeutics, Inc.)

Intarcia Announces Appointment Of Dr. Sunita Zalani As Vice President, Global Head Of Regulatory Affairs And Quality

 Intarcia Therapeutics, Inc. today officially announced the appointment of Sunita Zalani, Ph.D., as Vice President and Global Head of...

Jun 19, 2014, 10:32 ET
Tom Alessi, Ph.D. (PRNewsFoto/Intarcia Therapeutics, Inc.)

Chairman & CEO Kurt Graves Presents First "Key Disruptor Award" to Tom Alessi, Ph.D., for His Innovations in Chemistry and Manufacturing that Transform Medicines For Patients

 Intarcia Therapeutics, Inc. Chairman, President and CEO Kurt Graves late yesterday presented the very first "Chairman's Key Disruptor Award"...

Jun 15, 2014, 09:00 ET

Intarcia Presents Interim Phase 3 Data at ADA Showing ITCA 650, A Once Yearly GLP-1, Markedly Reduces Blood Sugar in Patients With Very Poorly Controlled Diabetes

  Intarcia Therapeutics, Inc. today announced the highlights of a poster presentation at the 74th Scientific Sessions of the American Diabetes...

Apr 01, 2014, 08:00 ET

Intarcia Secures Second Landmark Private Financing of $200 Million - Strengthens Position To Complete Phase 3, Prepare For Launch, and Build Pipeline

 Intarcia Therapeutics, Inc. today announced the completion of another landmark private round of equity financing for $200 million. Together...

Feb 26, 2014, 09:00 ET

Intarcia Appoints Jay Smith Head of Customer Experience & Outcomes

Intarcia Therapeutics, Inc. today formally announced the appointment of Jay Smith as Head of Customer Experience & Outcomes (CXO), an officer...

Jan 13, 2014, 08:50 ET

Intarcia CEO To Present Company Progress, Interim Phase 3 Data, And Key Milestones At J.P. Morgan

 Intarcia Therapeutics, Inc. today announced that Chairman, President and CEO Kurt Graves will present a Company overview today at the J.P....

Dec 02, 2013, 14:37 ET

Intarcia Therapeutics Appoints Nancy Thornberry to Board of Directors

 Intarcia Therapeutics, Inc. today announced the appointment of Nancy Thornberry to its Board of Directors. Nancy's exceptional 34-year career...

Sep 09, 2013, 09:36 ET

Intarcia Appoints Raymond Keane Vice President, General Counsel, And Chief Legal Officer

 Intarcia Therapeutics, Inc. today announced the appointment of Raymond T. Keane, Esq. to the position of Vice President, General Counsel and...

Jul 26, 2013, 08:35 ET

Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors

 Intarcia Therapeutics, Inc. today announced the appointment of Gino Santini to its Board of Directors. Mr. Santini is a former top executive...

Jul 17, 2013, 09:06 ET

Intarcia Therapeutics Appoints Dr. Eddie Li Vice President and Global Head of Regulatory Affairs

 Intarcia Therapeutics, Inc. today announced the hiring of Dr. Eddie Li to the newly created position of Vice President and Global Head of...

Jun 13, 2013, 16:18 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Supports American Diabetes Association Call For Independent Review Of Incretin-Based Therapies

Intarcia Therapeutics, Inc. today announced its support for the American Diabetes Association's (ADA) call for larger, longer-term, and more...

Mar 21, 2013, 09:12 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes

Intarcia Therapeutics, Inc. announced today the enrollment of the first patients in FREEDOM-1, the first of four planned Phase 3 clinical trials...

Feb 05, 2013, 09:06 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Appoints Owen Hughes Chief Business Officer and Head of Corporate Development

 Intarcia Therapeutics, Inc. today announced the appointment of Owen Hughes, Jr., to the position of Chief Business Officer (CBO) and Head of...

Nov 15, 2012, 10:58 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes

 Intarcia Therapeutics, Inc. today announced the simultaneous completion of two financings with total proceeds of $210 million, the largest...

Oct 03, 2012, 08:45 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Announces Presentation of Analysis Used for Dose Selection for Global ITCA 650 Phase 3 Program for Type 2 Diabetes at EASD

Intarcia Therapeutics, Inc. announced the presentation of an analysis of phase 2 clinical study results for ITCA 650 (continuous subcutaneous...

Sep 28, 2012, 09:30 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia to Present Analysis of Dose Selection for Global ITCA 650 Phase 3 Program for Type 2 Diabetes at EASD

 Intarcia Therapeutics, Inc. announced that an analysis of the results of a phase 2 clinical study of ITCA 650 (continuous subcutaneous...